UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 76 filers reported holding UROGEN PHARMA LTD in Q1 2019. The put-call ratio across all filers is 0.32 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $680,000 | -52.1% | 38,139 | -10.5% | 0.01% | 0.0% |
| Q4 2019 | $1,421,000 | +43.0% | 42,590 | +2.1% | 0.01% | +37.5% |
| Q3 2019 | $994,000 | -36.4% | 41,719 | -4.0% | 0.01% | -33.3% |
| Q2 2019 | $1,562,000 | -11.4% | 43,459 | -8.9% | 0.01% | 0.0% |
| Q1 2019 | $1,763,000 | +10.0% | 47,730 | +28.3% | 0.01% | 0.0% |
| Q4 2018 | $1,602,000 | +20.9% | 37,210 | +32.6% | 0.01% | +33.3% |
| Q3 2018 | $1,325,000 | +18.6% | 28,054 | +25.0% | 0.01% | +28.6% |
| Q2 2018 | $1,117,000 | +10.2% | 22,451 | +10.0% | 0.01% | -12.5% |
| Q1 2018 | $1,014,000 | +86.7% | 20,406 | +39.7% | 0.01% | +100.0% |
| Q4 2017 | $543,000 | +46.0% | 14,603 | +23.9% | 0.00% | +33.3% |
| Q3 2017 | $372,000 | +90.8% | 11,790 | +9.1% | 0.00% | +200.0% |
| Q2 2017 | $195,000 | – | 10,806 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |